



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Li *et al.*

Appl. No.: 09/518,381

Filed: March 3, 2000

For: **Human G-Protein Coupled  
Receptors**

Confirmation No.: 5756

Art Unit: 1646

Examiner: Basi, N.

Atty. Docket: 1488.1220002/EKS/PAJ

**RECEIVED**

**MAR 02 2004**

**First Supplemental Information Disclosure Statement Filing Under 37  
C.F.R. § 1.97(c)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on June 9, 2000 in connection with the above-captioned application. Copies of the documents are provided.

The Examiner's attention is directed to the following co-pending U.S. patent applications:

U.S. Application No. 09/518,383, Li *et al.*, filed March 3, 2000 and submitted herewith as document **AR8**; and

U.S. Application No. 09/827,937, Li *et al.*, filed April 9, 2001, published now as U.S. Published Application No. 2002/0052043 A1 and submitted herewith as document **AE1**;

which are directed to related technical subject matter. The identification of these U.S. patent applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the

merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$ 180.00 in payment of the fee under 37 C.F.R. § 1.17(p).


Documents AN1, AO1, and AS7 were cited in a European search report (Document AT7) by a foreign patent office in a counterpart foreign application. Submission of an English language version of the search report that indicates the degree of relevance found by the foreign office is provided in satisfaction of the requirement for a concise explanation of relevance. 1138 OG 37, 38.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Peter A. Jackman  
Attorney for Applicants  
Registration No. 45,986

Date: Feb. 24, 2004

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

FORM PTO-1449

ATTY. DOCKET NO.  
1488.1220002/EKS/PAJAPPLICATION NO.  
09/518,381FIRST NAMED INVENTOR  
Li *et al.*FILING DATE  
March 3, 2000ART UNIT  
1646FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1	2002/0052043 A1	05/02/2002	Li <i>et al.</i>			04/09/2001
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1	WO 91/15583 A1	10/17/1991	WIPO			Yes No
	AO1	WO 99/35106 A2	07/15/1999	WIPO			Yes No
	AP1						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS	4	Birkenbach, M., <i>et al.</i> , "Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors," <i>J. Virol.</i> 67:2209-2220, American Society for Microbiology (1993)
	AT	4	Chattaraj, S.C., "Cangrelor AstraZeneca," <i>Curr. Opin. Invest. Drugs</i> 2:250-255, PharmaPress Ltd. (February 2001)

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.  
1488.1220002/EKS/PAJAPPLICATION NO.  
09/518,381FIRST NAMED INVENTOR  
Li *et al.*FILING DATE  
March 3, 2000ART UNIT  
1646FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

MAR 02 2004

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Connelly, K.P. and De Witt, L.D., "Neurologic Complications of Infectious Mononucleosis," <i>Ped. Neurol.</i> 10:181-184, Elsevier Science Inc. (1994)
	AS	<u>5</u>	Grässer, F.A., <i>et al.</i> , "Monoclonal Antibodies Directed Against the Epstein-Barr Virus-Encoded Nuclear Antigen 1 (EBNA1): Immunohistologic Detection of EBNA1 in the Malignant Cells of Hodgkin's Disease," <i>Blood</i> 84:3792-3798, The American Society for Hematology (1994)
	AT	<u>5</u>	Hollopeter, G., <i>et al.</i> , "Identification of the platelet ADP receptor targeted by antithrombotic drugs," <i>Nature</i> 409:202-207, Nature Publishing Group (January 2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.  
1488.1220002/EKS/PAJAPPLICATION NO.  
09/518,381FIRST NAMED INVENTOR  
Li *et al.*FILING DATE  
March 3, 2000ART UNIT  
1646FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

MAR 02 2004

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	6	Kikuta, H., <i>et al.</i> , "Detection of Epstein-Barr virus DNA in cardiac and aortic tissues from chronic, active Epstein-Barr virus infection associated with Kawasaki disease-like coronary artery aneurysms," <i>J. Ped.</i> 123:90-92, Mosby-Year Book, Inc. (1993)
	AS	6	Schweickart, V.L., <i>et al.</i> , "Cloning of Human and Mouse EB11, a Lymphoid-Specific G-Protein-Coupled Receptor Encoded on Human Chromosome 17q12-q21.2," <i>Genomics</i> 23:643-650, Academic Press, Inc. (1994)
	AT	6	Tyson, A.A., Jr., <i>et al.</i> , "Acute Epstein-Barr Virus Myocarditis Simulating Myocardial Infarction With Cardiogenic Shock," <i>South. Med. J.</i> 82:1184-1187, Southern Medical Association (1989)

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO. 1488.1220002/EKS/PAJ	APPLICATION NO. 09/518,381
FIRST NAMED INVENTOR Li <i>et al.</i>	
FILING DATE March 3, 2000	ART UNIT 1646

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


RECEIVED  
MAR 02 2004

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>7</u>	Wang, K., <i>et al.</i> , "Blockade of the Platelet P2Y <sub>12</sub> Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model," <i>Arterioscler. Thromb. Vasc. Biol</i> 22:357-362, Lippincott, Williams & Wilkins (February 2003)
AS	<u>7</u>	Database EMBL, Accession No. AA254425, Marra, M., <i>et al.</i> , (first available March 1997)
AT	<u>7</u>	Partial European Search Report for European Application No. 03 01 5456, mailed December 17, 2003, European Patent Office, Netherlands

EXAMINER	DATE CONSIDERED
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



FORM PTO-1449

ATTY. DOCKET NO.  
1488.1220002/EKS/PAJAPPLICATION NO.  
09/518,381FIRST NAMED INVENTOR  
Li *et al.*FILING DATE  
March 3, 2000ART UNIT  
1646FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

MAR 02 2004

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	8	Copy of Co-Pending Non-Provisional U.S. Patent Application No. 09/518,383, Li <i>et al.</i> , filed March 3, 2000 (NOT PUBLISHED)
	AS		
	AT		

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.